Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Weichenthal

Showing results (71-80 of 167) with videos related to

Pageof 17
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 12, 2019
Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective dataWiebke Sondermann, Jochen Sven Utikal, Alexander H Enk, et al.
European Journal of Cancer (Oxford, England : 1990)|January 6, 2024
Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREGCorinna Kochanek, Catharina Gilde, Lisa Zimmer, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2019
Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmarkTitus J Brinker, Achim Hekler, Axel Hauschild, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 11, 2024
C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanomaJulian Kött, Noah Zimmermann, Tim Zell, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2019
Superior skin cancer classification by the combination of human and artificial intelligenceAchim Hekler, Jochen S Utikal, Alexander H Enk, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 7, 2005
Reduced Paneth cell alpha-defensins in ileal Crohn's diseaseJan Wehkamp, Nita H Salzman, Edith Porter, et al.
Journal of Medical Internet Research|February 2, 2021
Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model StudyMax Schmitt, Roman Christoph Maron, Achim Hekler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanomaAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trialAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
International Journal of Cancer|March 15, 2026
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO studyRalf Gutzmer, Michael Weichenthal, Thomas Eigentler, et al.
Pageof 17

Showing results (71-80 of 167) with videos related to

Sort By:
Pageof 17
European Journal of Cancer (Oxford, England : 1990)|August 12, 2019
Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective dataWiebke Sondermann, Jochen Sven Utikal, Alexander H Enk, et al.
European Journal of Cancer (Oxford, England : 1990)|January 6, 2024
Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREGCorinna Kochanek, Catharina Gilde, Lisa Zimmer, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2019
Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmarkTitus J Brinker, Achim Hekler, Axel Hauschild, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 11, 2024
C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanomaJulian Kött, Noah Zimmermann, Tim Zell, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2019
Superior skin cancer classification by the combination of human and artificial intelligenceAchim Hekler, Jochen S Utikal, Alexander H Enk, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 7, 2005
Reduced Paneth cell alpha-defensins in ileal Crohn's diseaseJan Wehkamp, Nita H Salzman, Edith Porter, et al.
Journal of Medical Internet Research|February 2, 2021
Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model StudyMax Schmitt, Roman Christoph Maron, Achim Hekler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanomaAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trialAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.
International Journal of Cancer|March 15, 2026
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO studyRalf Gutzmer, Michael Weichenthal, Thomas Eigentler, et al.
Pageof 17